Ovid Trifan

Dr. Trifan joined Apexigen in September of 2014 as Vice President, Clinical Development, and was promoted to Chief Medical Officer in January of 2017. Prior to joining Apexigen, Dr. Trifan served as Senior Medical Director in the Clinical Science group at Onyx Pharmaceuticals (acquired by Amgen), where he co-chaired the Onyx-Bayer joint development committee for the clinical development of Nexavar® (sorafenib) and Stivarga® regorafenib), and supported business development efforts of the company. Prior to joining Onyx, Dr. Trifan, served as Group Director at Bristol-Myers Squibb where he lead clinical development teams for Erbitux® (cetuximab), necitumumab, CT-322 and contributed to the development of Ixempra® (ixabepilone). Prior to that, he trained in clinical oncology research at Johnson & Johnson Pharmaceutical Research & Development and contributed to the development of Yondelis® (trabecitidin). His experience also encompasses the discovery of novel anti-cancer agents while working in the Oncology Discovery group at Pharmacia Corporation (acquired by Pfizer).

Dr. Trifan was awarded a Medical Degree and a Doctorate in Cell Biology from Carol Davila University of Medicine and Pharmacy in Bucharest, Romania; Dr. Trifan conducted postdoctoral research at the University of Connecticut Health Center.

Ovid Trifan is the Chief Medical Officer and Senior Vice President, Clinical Development at Apexigen, based in United States, North America. With a background in Biotechnology, Ovid Trifan has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.